Tenulin and isotenulin inhibit P-glycoprotein function and overcome multidrug resistance in cancer cells
Ying-Tzu Chang1, Charles C N Wang2, Jiun-Yi Wang3
1Department of Pharmacy, College of Pharmacy, China Medical University, 91 Hsueh-Shih Road, Taichung 40402, Taiwan, ROC.
Background:
Multidrug resistance (MDR) in cancer is one of the main obstacles in treatment with chemotherapy. Drug efflux through P-glycoprotein is the major mechanism involved in MDR. A potential strategy to provide the best possible clinical outcomes is to develop P-glycoprotein (P-gp) inhibitors from natural products.
Purpose:
The present study investigated the effects of the natural sesquiterpene lactone tenulin and its derivative isotenulin on human P-gp; the mechanisms of kinetic interactions were also explored.
Methods:
The human P-gp (ABCB1/Flp-In™-293) stable expression cells were established by using the Flp-In™ system. The effects of tenulin and isotenulin on cell viability were evaluated by SRB assays in established cell lines, sensitive cancer cell line (HeLaS3), and resistant cancer cell line (KB-vin). The transporter inhibition ability was evaluated by calcein-AM uptake assays. The P-gp inhibition kinetics of tenulin and isotenulin were evaluated by rhodamine123 and doxorubicin efflux assays. The ATPase activity was evaluated with the Pgp-Glo™ Assay System.
Results:
Tenulin and isotenulin significantly inhibited the P-gp efflux function by stimulating P-gp ATPase activity. Tenulin and isotenulin interacted with the effluxes of rhodamine 123 and doxorubicin through a competitive and noncompetitive mechanism, respectively. The combinations of tenulin and isotenulin with chemotherapeutic drugs significantly resensitized MDR cancer cells.
Conclusion:
These results suggested that tenulin and isotenulin are potential candidates to be developed for synergistic treatment of MDR cancers.
Insights
Natural compounds tenulin and isotenulin inhibit P-glycoprotein (P-gp) efflux, a key mechanism in multidrug resistance (MDR) cancer. These P-gp inhibitors resensitize MDR cancer cells to chemotherapy, offering potential for synergistic cancer treatment.
Area of Science:
- Pharmacology
- Biochemistry
- Oncology
Background:
- Multidrug resistance (MDR) in cancer is a major challenge in chemotherapy.
- P-glycoprotein (P-gp) mediated drug efflux is a primary cause of MDR.
- Natural products offer a promising avenue for developing novel P-gp inhibitors.
Purpose of the Study:
- To investigate the effects of tenulin and isotenulin on human P-gp.
- To explore the kinetic mechanisms of tenulin and isotenulin interactions with P-gp.
Main Methods:
- Established human P-gp expressing cells using the Flp-In™ system.
- Assessed cell viability, transporter inhibition, P-gp efflux kinetics, and ATPase activity.
- Utilized SRB assays, calcein-AM uptake, rhodamine123 and doxorubicin efflux assays, and Pgp-Glo™ Assay System.
Main Results:
- Tenulin and isotenulin significantly inhibited P-gp efflux by stimulating ATPase activity.
- Tenulin and isotenulin exhibited competitive and noncompetitive inhibition, respectively.
- Combinations of tenulin/isotenulin with chemotherapy resensitized MDR cancer cells.
Conclusions:
- Tenulin and isotenulin demonstrate potential as P-gp inhibitors.
- These compounds could be developed for synergistic treatment strategies in MDR cancers.
Related Concept Videos
Treatment Resistant Cancers
Feedback Inhibition
Matrix Proteoglycans and Glycoproteins
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
Resistivity
Resistance


